John Hernandez
RESMEDAbout John Hernandez
John Hernandez, age 58, is an independent director of ResMed (RMD), serving since 2021. He is Head of Health Impact at Google and brings 30+ years of health technology leadership with a focus on AI, real‑world evidence, and digital health; he holds a B.A. from the University of North Carolina at Chapel Hill, a master’s degree in health policy, and a Ph.D. from the RAND Graduate School. He serves on ResMed’s Compliance, Privacy & Quality (CPQ) Committee.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Head of Health Impact | 2018–present | Leads health impact initiatives across Alphabet properties, leveraging AI and real‑world evidence | |
| Abbott Laboratories | Vice President, Global Health Economics & Outcomes Research | 2010–2016 | Built outcomes evidence to support market access and value narratives |
| Boston Scientific | Vice President, Clinical Research & Health Economics | 2001–2010 | Clinical research and health economics leadership |
External Roles
| Company/Organization | Role | Tenure | Committees |
|---|---|---|---|
| Carmat SA (ALCAR.PA) | Director (public company) | 2021–2024 | Not disclosed |
| Public company directorships (current) | None | — | — |
Board Governance
| Item | Detail |
|---|---|
| Independence | Independent director (NYSE/ASX standards) |
| Board tenure | Director since 2021 (4 years as of 2025 record date) |
| Committees | Member: Compliance, Privacy & Quality (CPQ) |
| Committee chair roles | None (CPQ chaired by Harjit Gill) |
| Attendance FY2025 | Board: 6 meetings; CPQ: 5 meetings; 100% attendance recorded for committees and board (except Peter Farrell for one meeting) |
| Lead Independent Director | Ronald “Ron” Taylor |
| Executive sessions | Independent directors meet in executive session at each board meeting |
| Committee independence | All committees 100% independent; members meet NYSE/SEC committee independence standards |
Fixed Compensation
| Component | FY2025 Amount | Notes |
|---|---|---|
| Cash retainer | $70,000 | Standard non‑executive director retainer |
| Committee member fees | $0 | ResMed does not pay additional retainers to non‑chair committee members |
| Meeting fees | $0 | No per‑meeting fees disclosed |
| Chair fees (received) | $0 | Not a chair |
| Total cash (FY2025) | $70,000 | — |
| FY2026 retainer (effective 7/1/2025) | $75,000 | Equity value unchanged at $260,000 |
Performance Compensation
| Element | Details |
|---|---|
| Annual equity grant (type) | Restricted Stock Units (RSUs); all non‑exec directors elected 100% RSUs for FY2025 |
| Grant date | November 20, 2024 (RSUs) |
| Grant valuation | $259,909 (grant date fair value) |
| Grant price | $241.55 closing price on 11/20/2024 |
| Vesting | Full vest on earlier of: Nov 11 in the year after grant or next annual meeting; service‑based |
| Options in FY2025 | None granted to Hernandez (Option Awards column blank) |
| Change‑of‑control terms | If not continuing as a director post‑transaction, then outstanding unvested RSUs and options vest in full |
| Deferral | Director deferred equity plan available; Hernandez shows 0 deferred RSUs outstanding as of 6/30/2025 |
Note: Director compensation is not tied to operating performance metrics; directors receive cash retainers and time‑based equity aligned to shareholder interests .
Other Directorships & Interlocks
- Current public company boards: None .
- Prior public company board: Carmat SA (2021–2024) .
- Compensation committee interlocks: None reported for FY2025 (committee composed solely of independent directors; no interlocks disclosed) .
- Related‑party transactions: Board determined no specific relationships or transactions required consideration in independence determinations; related‑party transactions require Audit Committee approval per policy .
Expertise & Qualifications
- Healthtech leadership with AI/ML and real‑world evidence expertise; experience across big tech and medtech ecosystems .
- Education: B.A. (UNC‑Chapel Hill), master’s in health policy, Ph.D. (RAND Graduate School) .
- Published researcher and frequent lecturer on digital health strategy, health policy, and value‑based care topics .
Equity Ownership
| Metric (as of 6/30/2025) | Amount |
|---|---|
| Options outstanding | 2,575 |
| RSUs outstanding | 1,083 |
| Deferred RSUs outstanding | 0 |
| Director ownership guideline | 5× annual cash retainer ($350,000 based on FY2025 retainer) |
| Compliance status | In compliance (all non‑exec directors compliant except DelOrefice as a new member) |
| Hedging/Pledging | Prohibited for directors (no hedging, pledging, short sales) |
Governance Assessment
- Strengths for investor confidence:
- Independent director with 100% meeting attendance, serving on the CPQ committee that oversees global compliance, privacy, quality, and sustainability—well‑matched to his digital health/AI background .
- Strong alignment via equity: annual RSU grant with clear vesting and change‑of‑control provisions; director ownership guideline of 5× retainer and compliance achieved as of 6/30/2025 .
- No related‑party exposures requiring disclosure; robust related‑party review policy; hedging/pledging of stock prohibited .
- Board practices include executive sessions each meeting and fully independent committees, with an experienced Lead Independent Director .
- Watch items (no current red flags disclosed):
- Hernandez is a senior Google health leader; while no related‑party transactions are disclosed, ongoing monitoring for potential ecosystem overlaps is prudent. Board independence determination and CPQ oversight mitigate perceived risks .
- Say‑on‑pay support was 84% in Nov 2024—solid but below historical ~90%—reflecting dual‑listing dynamics; the board enhanced disclosure and continues engagement .
Overall: Hernandez brings differentiated AI/real‑world evidence expertise and strong engagement, with clear alignment through equity and policy safeguards. No attendance, compensation, or related‑party red flags disclosed.